Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Boulder Peptide 2024Boulder Peptide 2024
Not Confirmed
Not Confirmed
16-19 September, 2024
Not Confirmed
Not Confirmed
17-19 September, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Boulder Peptide 2024Boulder Peptide 2024
Industry Trade Show
Not Confirmed
16-19 September, 2024
Industry Trade Show
Not Confirmed
17-19 September, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/bms-bayer-takeda-pfizer-downsize-to-combat-cost-pressures-meet-restructuring-plans
16 Sep 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/cro/amgen-and-merck-become-first-industry-partners-academic-clinical-trial-diversity-initiative
13 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024-302247205.html
11 Sep 2024
// Nick Paul FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/viridians-eye-disease-drug-hits-phase-3-goals-advancing-push-topple-amgens-tepezza
10 Sep 2024
// FIERCE PHARMA
https://www.fiercepharma.com/marketing/eli-lilly-novo-nordisk-and-other-big-pharmas-back-oacs-your-weight-matters-campaign
09 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/amgen-presents-new-data-for-first-in-class-imdelltra-tarlatamab-dlle-in-small-cell-lung-cancer-at-wclc-2024-302241093.html
06 Sep 2024
// BIOSPACE
https://www.biospace.com/drug-development/amgen-plans-phase-iii-program-for-next-gen-obesity-drug-targeting-liver-and-kidney-diseases
Details:
Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month or older with CD19-+ve Philadelphia chromosome-ve B-ALL.
Lead Product(s): Blinatumomab
Therapeutic Area: Oncology Brand Name: Blincyto
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2024
Lead Product(s) : Blinatumomab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves BLINCYTO for B-ALL in Consolidation Phase
Details : Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month or older with CD19-+ve Philadelphia chromosome-ve B-ALL.
Brand Name : Blincyto
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 14, 2024
Details:
Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody which is being investigated for the treatment of pattients with Immunoglobulin G4-related disease.
Lead Product(s): Inebilizumab
Therapeutic Area: Immunology Brand Name: Uplizna
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2024
Lead Product(s) : Inebilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amgen’s trial brings new hope for IgG4-RD patients
Details : Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody which is being investigated for the treatment of pattients with Immunoglobulin G4-related disease.
Brand Name : Uplizna
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 06, 2024
Details:
Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody which is being investigated for the treatment of pattients with Immunoglobulin G4-related disease.
Lead Product(s): Inebilizumab
Therapeutic Area: Immunology Brand Name: Uplizna
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Lead Product(s) : Inebilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amgen: Positive Uplizna Phase 3 Trial in Immunoglobulin G4-Related Disease
Details : Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody which is being investigated for the treatment of pattients with Immunoglobulin G4-related disease.
Brand Name : Uplizna
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 05, 2024
Details:
Bkemv (eculizumab) is approved by FDA as the first interchangeable biosimilar to Soliris to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Lead Product(s): Eculizumab
Therapeutic Area: Rare Diseases and Disorders Brand Name: Bkemv
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Lead Product(s) : Eculizumab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves First Interchangeable Biosimilar for Two Rare Diseases
Details : Bkemv (eculizumab) is approved by FDA as the first interchangeable biosimilar to Soliris to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Brand Name : Bkemv
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 28, 2024
Details:
Imdelltra (tarlatamab-dlle) is the first and only DLL3-targeting Bispecific T-cell Engager therapy. It is approved for adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Lead Product(s): Tarlatamab
Therapeutic Area: Oncology Brand Name: Imdelltra
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2024
FDA Approves IMDELLTRA™ (TARLATAMAB-DLLE) for Small Cell Lung Cancer
Details : Imdelltra (tarlatamab-dlle) is the first and only DLL3-targeting Bispecific T-cell Engager therapy. It is approved for adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Brand Name : Imdelltra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 16, 2024
Details:
CX-904 is an investigational, masked, conditionally activated PROBODY T-cell engager designed to target the EGFR on cancer cells and the CD3 receptor on T cells. It is being evaluated for the treatment of advanced pancreatic cancer.
Lead Product(s): CX-904
Therapeutic Area: Oncology Brand Name: CX-904
Study Phase: Phase IProduct Type: Large molecule
Recipient: CytomX Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Lead Product(s) : CX-904
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : CytomX Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CX-904 is an investigational, masked, conditionally activated PROBODY T-cell engager designed to target the EGFR on cancer cells and the CD3 receptor on T cells. It is being evaluated for the treatment of advan...
Brand Name : CX-904
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 08, 2024
Details:
Tepezza (teprotumumab) is a fully human anti-IGF-1R monoclonal antibody, which is currently being evaluated, for the treatment of thyroid eye disease.
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Brand Name: Tepezza
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2024
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amgen to Submit Teprotumumab Marketing Authorization Application to The European Medicines Agency
Details : Tepezza (teprotumumab) is a fully human anti-IGF-1R monoclonal antibody, which is currently being evaluated, for the treatment of thyroid eye disease.
Brand Name : Tepezza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 26, 2024
Details:
Tezspire (tezepelumab) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ). Currently it is being investigated for chronic obstructive pulmonary disease.
Lead Product(s): Tezepelumab
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tezspire
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Lead Product(s) : Tezepelumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amgen to Present TEZSPIRE® Phase 2a Copd Data at ATS 2024
Details : Tezspire (tezepelumab) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ). Currently it is being investigated for chronic obstructive pulmonary disease.
Brand Name : Tezspire
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 16, 2024
Details:
Xgeva (denosumab) is a human monoclonal antibody and a RANK ligand inhibitor. Its new formulation is indicated for the treatment of patients with bone metastases.
Lead Product(s): Denosumab
Therapeutic Area: Oncology Brand Name: Xgeva
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
UK MHRA Approves New Formulation of Amgen’s XGEVA
Details : Xgeva (denosumab) is a human monoclonal antibody and a RANK ligand inhibitor. Its new formulation is indicated for the treatment of patients with bone metastases.
Brand Name : Xgeva
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 01, 2024
Details:
Under the agreement, Amgen will develop, manufacture, and commercialize a subcutaneous formulation of Tepezza (teprotumumab) using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED).
Lead Product(s): Teprotumumab
Therapeutic Area: Immunology Brand Name: Tepezza
Study Phase: PreclinicalProduct Type: Large molecule
Recipient: Xeris Pharmaceuticals
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2024
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Xeris Pharmaceuticals
Deal Size : $75.0 million
Deal Type : Licensing Agreement
Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject® Formulation of...
Details : Under the agreement, Amgen will develop, manufacture, and commercialize a subcutaneous formulation of Tepezza (teprotumumab) using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED).
Brand Name : Tepezza
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 10, 2024
Inspections and registrations
ABOUT THIS PAGE
Amgen Inc is a supplier offers 9 products (APIs, Excipients or Intermediates).
Find a price of AMG 191 DRUG SUBSTANCE bulk with DMF offered by Amgen Inc
Find a price of AMG 157 (TEZEPELUMAB) PHASE 3 CMC AMENDMENT (DRUG SUBSTANCE AND DRUG PRODUCT) bulk with DMF offered by Amgen Inc
Find a price of AMG 191 DRUG PRODUCT bulk with DMF offered by Amgen Inc
Find a price of INTRAVENOUS SOLUTION STABILIZER (IVSS) bulk with DMF offered by Amgen Inc
Find a price of AMG 191 CELL LINE DEVELOPMENT bulk with DMF offered by Amgen Inc
Find a price of AMG 282 DRUG SUBSTANCE bulk with DMF offered by Amgen Inc
Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-015)(SP2/0,- AG14 CELLS, MEDAREX) TO IL15 bulk offered by Amgen Inc
Find a price of BULK PURIFIED MURINE MONOCLONAL ANTIBODY (ABX-CBL) TO BLAST CELLS bulk offered by Amgen Inc
Find a price of HUMAN MONOCLONAL ANTIBODY (ABX-EGF) TO EPIDERMAL GROWTH FACTOR RECEPTOR bulk offered by Amgen Inc
LOOKING FOR A SUPPLIER?